כנס ESMO 2024 יערך בברצלונה בתאריכים 13-17.9.2024. אל תעשו תכניות להסתובב בעיר כי הכנס יכלול מגוון עצום של הרצאות מעניינות.

לתכנית המלאה, לחץ/י כאן

להלן רשימה חלקית של הרצאות מומלצות.

אבסטרקטים:

LBA58 - A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG - Trevor Leong (Melbourne, Australia)
14.9.24 08:30 - 08:40
Madrid Auditorium - Hall 2

LBA59 - Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial - Sylvie Lorenzen (Munich, Germany)
14.9.24 08:40 - 08:50
Madrid Auditorium - Hall 2

1400O - Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma - Sara Lonardi (Padova, Italy)
14.9.24 09:15 - 09:25
Madrid Auditorium - Hall 2

1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) - Yelena Y. Janjigian (New York, United States of America, NY)
14.9.24 09:25 - 09:35
Madrid Auditorium - Hall 2

LBA2 - POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy - Sheela Rao (London, United Kingdom)
14.9.24 16:52 - 17:04
Barcelona Auditorium - Hall 2

LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study - Josep Llovet (Barcelona, Spain)
14.9.24 17:36 - 17:48
Barcelona Auditorium - Hall 2

515MO - Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI) - Josep Tabernero (Barcelona, Spain)
14.9.24 14:45 - 14:50
Granada Auditorium - Hall 6

516MO - Zanidatamab (Zani) + Chemotherapy (CT) in First-Line (1L) Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC) - Sun Young Rha (Seoul, Korea, Republic of)
14.9.24 14:50 - 14:55
Granada Auditorium - Hall 6

508MO - Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial - Syrine Ben Dhia (Nice, France)
14.9.24 15:15 - 15:20
Granada Auditorium - Hall 6

510MO - Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors - Kaysia Ludford (Houston, United States of America)
14.9.24 15:20 - 15:25
Granada Auditorium - Hall 6

505O - Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study - Salvatore Siena (Milan, Italy)
15.9.24 15:05 - 15:15
Madrid Auditorium - Hall 2

1402MO - An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer - Margaret M. Lee (Box Hill, Australia)
16.9.24 08:35 - 08:40
Bilbao Auditorium - Hall 2

 ועוד המוני נושאים מרתקים:

• סוגיות כירורגיות בגידולי GEJי(15.9.24 14:45 - 16:15 Bilbao Auditorium - Hall 2)
• ESMO guidelines mCRC (15.09.2024 10:15 - 11:45 Granada Auditorium - Hall 6)
• טיפול ב-HCC בשלב מקומי ומתקדם (16.09.2024 10:15-11:30 Sevilla Auditorium - Hall 2)
• End points חדשים במחקרים קליניים (13.09.2024 14:00 - 15:30 Alicante Auditorium - Hall 3)
• ביומרקרים ותרופות חדשות: בלבלב וקיבה (14.09.2024 10:15 - 11:45 Madrid Auditorium - Hall 2)
  בדרכי מרה (14.09.2024 15:00-15:45 Santander Auditorium - Hall 5)
• שינויי אקלים והשפעתם על אונקולוגיה (14.09.2024 10:00 - 11:00 Tarragona Auditorium - Hall 7)
• הגישה ל-Oligo progressionי(16.9.2024 14:45-16:15 Granada Auditorium - Hall 6) וטיפול Beyond progressionי(16.9.2024  14:45 - 16:00 Valencia Auditorium - Hall 5)
• תופעות לוואי אימונולוגית – לבביות GIי(16.09.2024 14:45 - 16:15 Toledo Auditorium - Hall 3)
• שימוש בבדיקת ctDNA/MRD
• תרופות חדשות מסוג ADC
• ויטמין D:

LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) - Kimmie Ng (Boston, United States of America)
15.9.24  15:35 - 15:45
Madrid Auditorium - Hall 2

לא לשכוח לכבד את פרופ' אירית בן אהרון בסשן שהיא מובילה:

Young onset of colorectal cancer: What do we need to know

 14.09.2024   10:45 - 11:30

Chair: Irit Ben-Aharon (Haifa, Israel)

Pamplona Auditorium - Hall 3

הירשמו לקבלת עדכונים בנושאים שעלו בכתבה